Mailed DNA tests could help families catch cancer early
NCT ID NCT06284330
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at whether mailing at-home genetic testing kits to relatives of people with hereditary cancer gene variants could increase the number of relatives who get tested. Researchers compared this approach to usual care in 108 participants. The goal was to see if making testing easier helps families learn about their cancer risk.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Direct mailed at-home genetic testing kit
- What this could lead to
- If successful, this approach could help more at-risk relatives get tested for hereditary cancer genes, potentially catching cancer earlier.
- What could go wrong
- This is a small feasibility study (108 participants) in one state, so results may not apply broadly. The intervention may not significantly increase testing rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
108 people
The number who actually took part.
- Started
-
Feb 2024
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Proband Inclusion Criteria: * Have a newly reported pathogenic or likely pathogenic variant in one or more of the following genes: APC, ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, MLH1, MSH2, MSH6, PMS2, PTEN, TP53 * 18 years of age or older * English fluency * Have at least 1 adult living genetically related relative who resides in Texas Proband Exclusion Criteria: * Referred for genetic testing by a relative with a pathogenic variant * Unwilling to be randomized to a study arm Relative Inclusion Criteria: * 18 years of age or older * English fluency * Residing in Texas
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hereditary cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a digital guide boost genetic testing in prostate cancer survivors?
- New digital platform aims to break the silence around hereditary cancer in families
- New study aims to unlock why lynch syndrome patients still get cancer despite surveillance
- Can a website replace the genetic counselor? new study tests online cancer risk testing
- 50,000 samples to unlock secrets of hereditary tumors
- Chatbot aims to close genetic testing gap for black cancer survivors